Response to the Comment on "Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer's Disease Diagnosis in Cognitively Impaired Patients"

J Gerontol A Biol Sci Med Sci. 2023 Jul 8;78(7):1307-1308. doi: 10.1093/gerona/glad094.

Authors

Matthieu Lilamand^{1

2}, Elodie Bouaziz-Amar^{1

3}, Julien Dumurgier^{1

2}, Emmanuel Cognat^{1

2}, Claire Hourregue², François Mouton-Liger¹, Manuel Sanchez^{1

4}, Anne-Cécile Troussière⁵, Matthieu Martinet¹, Jacques Hugon^{1

2}, Claire Paquet^{1

2}

Affiliations

¹ Inserm Unit, UMR-S 1144, Université Paris Cité, Paris, France.
² Cognitive Neurology Center, Lariboisière-Fernand Widal Hospital GHU AP-HP.Nord, Paris, France.
³ Biochemistry Department, Lariboisière Hospital GHU AP-HP.Nord, Paris, France.
⁴ Department of Geriatrics, Bichat GHU AP-HP.Nord, Paris, France.
⁵ Neurologist, 23 Esp. du Grand Siècle, 78000 Versailles, France.

PMID: 37208788
DOI: 10.1093/gerona/glad094

No abstract available

Publication types

Comment

MeSH terms

Alzheimer Disease* / diagnosis
Amyloid beta-Peptides
Amyloidogenic Proteins
Biomarkers
Humans
Leptin

Substances

Amyloid beta-Peptides
Amyloidogenic Proteins
Biomarkers
Leptin